Precipio Reports Q3 Revenue of $7.3 Million

The New Haven diagnostics company posted 8% year-over-year revenue growth and positive Adjusted EBITDA for the third quarter of 2026.

Updated on Nov. 10, 2026 in Economic Indicators

Precipio Reports Q3 Revenue of $7.3 Million

Precipio, Inc. reported third-quarter 2026 revenue of $7.3 million, up 8% from $6.8 million in the same period of 2025. The company also reported positive Adjusted EBITDA of $0.4 million and operating cash flow of $0.6 million for the quarter.

Why it matters

Precipio's results show growth in both its product line and its pathology business, with product revenue rising 40% year-over-year. Management says the company is positioned to accelerate commercialization of its existing product portfolio and to pursue longer-term growth opportunities.

Precipio's third-quarter revenue grew 8% year-over-year to $7.3 million, with product revenue up 40% to $1.0 million and pathology revenue up 5% to $6.3 million, according to company-reported figures. The filing does not break out how much of the growth came from pricing versus volume.

The players

Precipio, Inc.

A New Haven, Connecticut-based diagnostics company that develops proprietary diagnostic products and operates a pathology business.

The details

Precipio's pathology business generated most of the quarter's revenue and serves as the platform for validating its proprietary diagnostic products. The company's cash balance exceeded $3.5 million at quarter's end, up from $2.3 million a year earlier, and it generated $0.6 million in cash from operations.

Timeline

  1. Q3-2025: year-over-year comparison period for the reported results.

  2. Q2-2026: sequential comparison period, when revenue was $7.0 million.

  3. September 30, 2026: end of the third-quarter reporting period.

  4. November 10, 2026: third-quarter financial results were announced.

  5. November 10, 2026, 5 p.m. ET: shareholder call scheduled to discuss the results and take questions.

Economic Indicators Context

Precipio's 8% year-over-year revenue growth in Q3-2026 is measured against its own Q3-2025 base of $6.8 million, so the result reflects company-specific progress rather than broader sector performance. The quarter's cash balance rose from $2.3 million to above $3.5 million over the same period.

For shareholders and prospective investors, the results show revenue and cash both growing year-over-year, though the figures are company-reported and unaudited. Anyone tracking the stock should weigh the quarter's 8% revenue gain against the company's reliance on its pathology business for most of its sales.

The takeaway

Precipio's growth is concentrated in its product line, which rose 40% year-over-year, while pathology grew a more modest 5%. Watching whether product revenue keeps that pace will indicate whether the company's commercialization plans are gaining traction.

What happens next

Precipio is scheduled to hold a shareholder call on November 10, 2026, at 5 p.m. ET to discuss third-quarter performance and take questions.

Further reading

Track the latest company earnings and related data in our Economic Indicators section.

Source note: This article includes information reported by The Manila times.